What is IGC Pharma Cash-to-Debt?
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. IGC Pharma's cash to debt ratio for the quarter that ended in Dec. 2023 was 3.66.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, IGC Pharma could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.
The historical rank and industry rank for IGC Pharma's Cash-to-Debt or its related term are showing as below:
IGC'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.15 Med: 3.41 Max: 512.2
Current: 3.66
During the past 13 years, IGC Pharma's highest Cash to Debt Ratio was 512.20. The lowest was 0.15. And the median was 3.41.
IGC Pharma Cash-to-Debt Historical Data
The historical data trend for IGC Pharma's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
IGC Pharma Cash-to-Debt Chart
|
IGC Pharma Annual Data
|
|
Trend |
Mar14 |
Mar15 |
Mar16 |
Mar17 |
Mar18 |
Mar19 |
Mar20 |
Mar21 |
Mar22 |
Mar23 |
| Cash-to-Debt |
|
Get a 7-Day Free Trial
|
|
|
512.20 |
23.06 |
14.85 |
17.20 |
6.97 |
|
IGC Pharma Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Cash-to-Debt |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
9.83 |
6.97 |
4.35 |
7.53 |
3.66 |
Competitive Comparison of IGC Pharma's Cash-to-Debt
For the Biotechnology subindustry, IGC Pharma's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IGC Pharma's Cash-to-Debt Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, IGC Pharma's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where IGC Pharma's Cash-to-Debt falls into.
IGC Pharma Cash-to-Debt Calculation
This is the ratio of a company's
Cash, Cash Equivalents, Marketable Securities
to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.
IGC Pharma's Cash to Debt Ratio for the fiscal year that ended in Mar. 2023 is calculated as:
IGC Pharma's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IGC Pharma (IGC Pharma) Business Description
Traded in Other Exchanges
Address
10224 Falls Road, Potomac, MD, USA, 20854
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.
Executives
| James P Moran |
director |
914 SPRING HILL ROAD, MCLEAN VA 22102 |
| John Edward Lynch |
director |
14 PARK AVENUE, REHOBOTH BEACH DE 19971 |
| Richard K Prins |
director |
|
| Ram Mukunda |
director, officer: Exec. Chairman & CEO |
|
| Claudia Grimaldi |
officer: Vice president and PFO |
PO BOX 60642, POTOMAC MD 20859 |
| Rohit Goel |
officer: Manager & PAO |
PO BOX 60642, POTOMAC MD 20859 |
| John Cherin |
officer: CFO, Treasurer and PAO |
662 LIVE OAK DRIVE, MCLEAN VA 22101 |
| Shu Kwong Ngai |
director, officer: Interim CFO |
4336 MONTGOMERY AVENUE, BETHESDA MD 20814 |
| Ranga C Krishna |
director |
330 THORNTON ROAD, ENGLEWOOD X1 07631 |
| Sudhakar V Shenoy |
director |
10411 MOTOR CITY DRIVE, BETHESDA MD 20817 |
| Suhail Nathani |
director |
INDIA GLOBALIZATION CAPITAL, INC., 4336 MONTGOMERY AVE., BETHESDA MD 20814 |
| Nisswa Acquisition Master Fund Ltd. |
10 percent owner |
C/O MAPLES CORPORATE SVCS LIMITED, PO BOX 309, UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104 |
| Smith Edward B Iii |
10 percent owner |
C/O BRIGHTLINE CAPITAL MANAGEMENT, LLC, 1120 AVE OF THE AMERICAS, SUITE 1505, NEW YORK NY 10036 |
| Ag Ubs |
10 percent owner |
600 WASHINGTON BLVD., STAMFORD CT 06901 |
| Pine River Master Fund Ltd. |
10 percent owner |
C/O PINE RIVER CAPITAL MANAGEMENT L.P., 601 CARLSON PARKWAY, 7TH FLOOR, MINNETONKA MN 55305 |
IGC Pharma (IGC Pharma) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
IGC has been successfully added to your